Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The firm products include IXINITY, Rasuvo, Metoject, Rupall, and Gleolan. The company was founded in 2003 and is headquartered in Bolton, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company